- Home
- CLPR vs RFL Comparison
CLPR vs RFL Comparison
Compare CLPR & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLPR | RFL |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Real Estate |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 61.1M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CLPR | RFL |
|---|---|---|
| Price | $3.25 | $1.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 58.6K | ★ 58.8K |
| Earning Date | 06-05-2026 | 03-30-2026 |
| Dividend Yield | ★ 12.34% | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,997,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.82 | ★ 43.96 |
| 52 Week Low | $3.10 | $1.12 |
| 52 Week High | $4.68 | $3.19 |
Technical Indicators
Market Signals| Indicator | CLPR | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 37.13 | 76.62 |
| Support Level | N/A | $1.41 |
| Resistance Level | $3.96 | $1.60 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 28.58 | 75.61 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.